Research and Markets (http://www.researchandmarkets.com/research/s5tpn9/baricitinib)
has announced the addition of GlobalData's new report "Baricitinib
(Rheumatoid Arthritis) Forecast and Market Analysis" to their offering.
GlobalData has released its new PharmaPoint Drug Evaluation report,
Baricitinib (Rheumatoid Arthritis) Forecast and Market Analysis. The RA
market is currently very dynamic, with the November 6, 2012 FDA approval
of Pfizer's Xeljanz (tofacitinib) and novel oral therapies awaiting
approval such as: Eli Lilly's anti-BAFF, tabalumab and JAK1,2 inhibitor,
baricitinib, and Rigel/AZ's SYK inhibitor, fostamatinib. These compounds
will challenge the current biologics in the attempt to dislodge the
stronghold of the TNF inhibitors, if their safety and efficacy profiles
are proven once they enter the market.
Eli Lilly and Company and Incyte Corporation are jointly developing
baricitinib, an oral JAK1 and 2 inhibitor, under a worldwide license and
collaboration agreement in which Lilly has the licensing rights.
Baricitinib prevents intracellular signaling of IL-6 and IL-23, thereby
reducing inflammation. Formerly known as LY3009104 to Lilly and as
INCB28050 to Incyte, baricitinib is currently in Phase IIb clinical
trials to study patients with active RA on background MTX. This trial is
located in nine countries including the US and India. In addition to RA,
baricitinib is in Phase IIb trials for the treatment of moderate to
severe plaque psoriasis.
- Overview of RA, including epidemiology, etiology, symptoms, diagnosis,
pathology and treatment guidelines as well as an overview on the
- Detailed information on Baricitinib including product description,
safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Baricitinib for the top eight countries from 2011
- Sales information covered for the US, France, Germany, the UK, Italy,
Spain, Japan and Australia.
Key Topics Covered:
1 List of Tables and Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Opportunity and Unmet Need
7 Pipeline Assessment
8 Baricitinib (formerly LY3009104/INCB28050)
For more information visit http://www.researchandmarkets.com/research/s5tpn9/baricitinib
[ Back To NFVZone's Homepage ]